Barcelona, Spain – July 2, 2025 – ADmit Therapeutics, a biotechnology company focused on developing innovative diagnostic solutions for Alzheimer’s disease, today announced its relocation to new, expanded laboratory and office spaces within Almirall’s Innovation Hub “The Hive” at the existing R&D center in Sant Feliu de Llobregat.
This strategic move signifies a key milestone for ADmit Therapeutics, providing access to enhanced infrastructure and fostering even closer collaboration within the vibrant scientific ecosystem at “The Hive.” The new facilities offer increased capacity and cutting-edge resources to accelerate the company’s research and development efforts in the fight against Alzheimer’s and other neurodegenerative diseases.
“We are thrilled to establish our new home within ‘the Hive’,” said Marta Barrachina, CEO and Co-Founder of ADmit Therapeutics. “This relocation not only provides us with superior facilities but also strengthens our ties with a leading pharmaceutical company, creating a synergistic environment that will undoubtedly propel our mission to bring an early diagnostic test for Alzheimer’s disease to patients sooner.”
“Welcoming ADmit to The Almirall Innovation Hub marks a pivotal milestone in our journey towards open collaboration and becoming part of a dynamic science exchange ecosystem – one that fosters industry synergies and strategic partnerships to help transform lives”, said Marc Soriano, Executive Director R&D Project, Portofolio and Partner Excellence at Almirall.
The move is effective immediately, with all operations now fully transitioned to the new location after the on-site audit by regulatory agencies.
About ADmit Therapeutics
ADmit Therapeutics is a biotechnology company dedicated to the commercialization of an early, non-invasive diagnostic test for Alzheimer’s disease dementia. The company’s innovative approach aims to identify the disease in its earliest stages, enabling timely intervention and potentially altering its progression. The MAP-AD® Test is poised to revolutionize the prognosis of Alzheimer’s dementia, optimizing patient stratification for clinical trials and for personalized medicine.
About Almirall
Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients’ world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients´ needs.
Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2024: €990 MM, over 2000 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.
